← Russell 3000 cross-section

PALI PALISADE BIO, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-10, not restated
Healthcare

Scale

Market cap
$376m
Revenue TTM
$0m
Net income TTM
$-32m
Free cash flow
Composite score
Sector rank
#2539

Valuation

P / E
EV / EBITDA
EV / sales
500.8
FCF yield
Earnings yield vs 10-yr
-13.22pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-6,388.2%
EBITDA margin
-7,069.6%
ROE
-26.2%
ROIC
Revenue growth

Insider activity, last 90 days

Net open-market
$-0.16m
Buyers
1
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

The increase in research and development employee-related expenses for the three months ended June 30, 2026, compared to the three months ended June 30, 2025, was primarily due to an approximately $2.0 million increase in non-cash share-based compensation expense and an approximately $0.6 million increase in research and development salaries and benefits expense due to higher research and development headcount necessary to support our PALI-2108 development strategy. …PALISADE BIO, INC., 10-Q, period ended 2026-06-30, filed 2026-08-10

Read the full passage →